Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Estimating renal function in old people: an in-depth review.

Raman M, Middleton RJ, Kalra PA, Green D.

Int Urol Nephrol. 2017 Nov;49(11):1979-1988. doi: 10.1007/s11255-017-1682-z. Epub 2017 Sep 15. Review.

2.

New Model for Estimating Glomerular Filtration Rate in Patients With Cancer.

Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H.

J Clin Oncol. 2017 Aug 20;35(24):2798-2805. doi: 10.1200/JCO.2017.72.7578. Epub 2017 Jul 7.

PMID:
28686534
3.

Cockcroft-Gault revisited: New de-liver-ance on recommendations for use in cirrhosis.

Scappaticci GB, Regal RE.

World J Hepatol. 2017 Jan 28;9(3):131-138. doi: 10.4254/wjh.v9.i3.131. Review.

4.

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.

Beumer JH, Ding F, Tawbi H, Lin Y, Viluh D, Chatterjee I, Rinker M, Chow SL, Ivy SP.

J Clin Oncol. 2016 Jan 10;34(2):110-6. doi: 10.1200/JCO.2014.59.7302. Epub 2015 Sep 21.

5.

Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.

Horowitz NS, Wright AA.

Gynecol Oncol. 2015 Jul;138(1):201-6. doi: 10.1016/j.ygyno.2015.04.002. Epub 2015 Apr 12. Review.

6.

Kidney function, endothelial activation and atherosclerosis in black and white Africans with rheumatoid arthritis.

Dessein PH, Hsu HC, Tsang L, Millen AM, Woodiwiss AJ, Norton GR, Solomon A, Gonzalez-Gay MA.

PLoS One. 2015 Mar 25;10(3):e0121693. doi: 10.1371/journal.pone.0121693. eCollection 2015.

7.
8.

Variability of glomerular filtration rate estimation equations in elderly Chinese patients with chronic kidney disease.

Liu X, Cheng MH, Shi CG, Wang C, Cheng CL, Chen JX, Tang H, Chen ZJ, Ye ZC, Lou TQ.

Clin Interv Aging. 2012;7:409-15. doi: 10.2147/CIA.S36152. Epub 2012 Oct 11.

9.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR.

J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.

10.

High-dose chemotherapy and stem cell transplantation for advanced testicular cancer.

Voss MH, Feldman DR, Motzer RJ.

Expert Rev Anticancer Ther. 2011 Jul;11(7):1091-103. doi: 10.1586/era.10.231. Review.

11.

A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.

Morgan MA, Sill MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS.

Gynecol Oncol. 2011 May 1;121(2):264-8. doi: 10.1016/j.ygyno.2010.12.358. Epub 2011 Feb 1.

12.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.

Lassen U, Molife LR, Sorensen M, Engelholm SA, Vidal L, Sinha R, Penson RT, Buhl-Jensen P, Crowley E, Tjornelund J, Knoblauch P, de Bono JS.

Br J Cancer. 2010 Jun 29;103(1):12-7. doi: 10.1038/sj.bjc.6605726. Epub 2010 Jun 15.

13.

A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.

Tiersten AD, Sill MW, Knight D, Muggia F, Garcia AA, Swensen R, Warshal DP, Mannel RS, Fracasso PM.

Gynecol Oncol. 2010 Sep;118(3):303-7. doi: 10.1016/j.ygyno.2010.05.020. Epub 2010 Jun 14.

14.

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR.

J Clin Oncol. 2010 Jun 1;28(16):2727-31. doi: 10.1200/JCO.2009.26.8326. Epub 2010 Apr 26.

15.

Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004.

Snyder JJ, Foley RN, Collins AJ.

Am J Kidney Dis. 2009 Feb;53(2):218-28. doi: 10.1053/j.ajkd.2008.07.034. Epub 2008 Oct 31.

16.

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

17.

Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB.

Antimicrob Agents Chemother. 2006 Nov;50(11):3701-7. Epub 2006 Aug 28.

18.

Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, García MJ.

Antimicrob Agents Chemother. 2005 Dec;49(12):4934-41.

19.

Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S.

Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):808.

20.

Renal outcome in adults with renal insufficiency and irregular asymmetric kidneys.

Neild GH, Thomson G, Nitsch D, Woolfson RG, Connolly JO, Woodhouse CR.

BMC Nephrol. 2004 Oct 5;5:12. Review.

Supplemental Content

Support Center